centanafadine   Click here for help

GtoPdb Ligand ID: 14621

Synonyms: DOV 216,419 | DOV-216419 | EB-1020 | Simtriyo®
Approved drug PDB Ligand
centanafadine is an approved drug
Compound class: Synthetic organic
Comment: Centanafadine (EB-1020) is a triple monoamine reuptake inhibitor [1-2,4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 12.03
Molecular weight 209.29
XLogP 2.46
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC2=C(C=C1)C=C(C=C2)[C@]34C[C@]4([H])CNC3
Isomeric SMILES [C@@]12([C@](C1)(CNC2)[H])C3=CC4=C(C=C3)C=CC=C4
InChI InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
InChI Key HKHCSWPSUSWGLI-CABCVRRESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. (2012)
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
Synapse, 66 (6): 522-32. [PMID:22298359]
2. Ji J, Hu Z, Zheng F, Zheng J, Cheng J, Zayniddin N, Abduahadi S, Wang G, Gong X, Pan L et al.. (2025)
D-morphinan analogs with favorable pharmacokinetic profiles as dual-acting antidepressants.
Eur J Med Chem, 287: 117349. [PMID:39952098]
3. Kang C. (2026)
Centanafadine: First Approval.
Drugs, [Epub ahead of print]. [PMID:42925388]
4. Li Y, Meng Y, Li N, Zhao J, Li R, Bai Q, Wang G, Zhao Y. (2025)
Structural basis for pharmacotherapeutic action of triple reuptake inhibitors.
Nat Commun, 17 (1): 61. [PMID:41392177]
5. Nageye F, Cortese S. (2019)
Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD.
Expert Rev Neurother, 19 (7): 707-717. [PMID:31167583]
6. Veronesi GF, Gabellone A, Tomlinson A, Solmi M, Correll CU, Cortese S. (2024)
Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults.
Neurosci Biobehav Rev, 163: 105774. [PMID:38914177]
7. Wilens TE, Oberdhan D, Jin N, Skubiak T, Childress AC, van Stralen J, Ward CL. (2026)
Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
J Child Adolesc Psychopharmacol, 36 (5): 266-277. [PMID:41958186]